Avet Lifesciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Avet Lifesciences Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $6.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Avet Lifesciences Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $6.5M Trade | TransData Nexus

Avet Lifesciences Private Limited

Indian Pharmaceutical Exporter · Diuretics Specialist · $6.5M Total Trade · DGFT Verified

Avet Lifesciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $6.5M across 3 products in 3 therapeutic categories. Based on 135 verified export shipments from Indian Customs (DGFT) records, Avet Lifesciences Private Limited is the #1 Indian exporter in 1 product including Amikacin. Top exports include Furosemide ($2.7M), Amikacin ($2.4M), Metoclopramide ($1.5M).

Avet Lifesciences Private Limited — Export Portfolio & Destination Treemap

Avet Lifesciences Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Avet Lifesciences Private Limited? — Company Overview & Market Position

Avet Lifesciences Private Limited, established on August 26, 2020, is a pharmaceutical manufacturing company headquartered in Pune, Maharashtra, India. The company specializes in the formulation and development of finished pharmaceutical products, including tablets, capsules, syrups, and injections. Registered under the Corporate Identification Number (CIN) U24299PN2020PTC193397, Avet Lifesciences operates as a private unlisted entity. The authorized capital stands at ₹20.00 crore, with a paid-up capital of ₹15.45 crore. As of April 4, 2024, the company employed 28 professionals.

What Does Avet Lifesciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Furosemide$2.7M 2Amikacin$2.4M 3

Product Portfolio — Top 3 by Export Value

Avet Lifesciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Furosemide	Diuretics	$2.7M	58	3.8%	5
2	Amikacin	Advanced Antibiotics	$2.4M	47	11.1%	1
3	Metoclopramide	Gastrointestinal	$1.5M	30	6.6%	2

Avet Lifesciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $6.5M. The company is the #1 Indian exporter in 1 product: Amikacin. The top category is Diuretics (41.1% of portfolio), followed by Advanced Antibiotics (36.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Avet Lifesciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Avet Lifesciences Private Limited's manufacturing facility is located at A-402, 4th Floor, Ganga Osian Square, Survey No. 249/250, Tal – Mulshi, Wakad, Pune, Maharashtra, 411057. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly disclosed.

3Key Leadership

The leadership team at Avet Lifesciences Private Limited includes:

Ulhas Rajaram Puranik: Director, appointed on September 22, 2021.

Brijmohan Sharma: Director, appointed on September 6, 2021.

Mandar Chintaman Joshi: Company Secretary, appointed on July 17, 2023.

Nikhil Deepak Shah: Chief Financial Officer (CFO), appointed on September 15, 2022.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Avet Lifesciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Avet Lifesciences Private Limited has engaged in the export of finished pharmaceutical formulations to various international markets. Between 2022 and 2026, the company reported a total export value of $6.5 million USD across 135 shipments, encompassing three products across three therapeutic categories. The top three products exported were Amikacin ($2.4 million, 11.1% market share), Metoclopramide ($1.5 million, 6.6% market share), and Furosemide ($2.7 million, 3.8% market share). The primary therapeutic categories included Advanced Antibiotics (36.0%), Diuretics (41.1%), and Gastrointestinal (23.0%). Notably, Avet Lifesciences holds the position of the number one market leader in Amikacin. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its export value.

2Emerging Markets

Avet Lifesciences Private Limited has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's focus on obtaining WHO prequalification for its products has facilitated access to these markets, enabling the distribution of high-quality pharmaceutical formulations to a broader global audience. Specific details regarding market penetration and regulatory approvals in these regions are not publicly disclosed.

Geographic Strategy

Avet Lifesciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Avet Lifesciences Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's export activities to the United States suggest compliance with FDA regulations; however, comprehensive information is not disclosed.

2WHO & EU GMP

Avet Lifesciences Private Limited has pursued compliance with international Good Manufacturing Practice (GMP) standards, including those set by the World Health Organization (WHO) and the European Union (EU). Obtaining WHO prequalification for its products has enabled the company to access emerging markets. Specific details regarding EU GMP certifications and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed.

3CDSCO & Indian Regulatory

Avet Lifesciences Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) and other regulatory approvals are not publicly disclosed.

Avet Lifesciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Avet Lifesciences Private Limited operates in a competitive pharmaceutical export market, with key competitors in overlapping therapeutic categories such as Advanced Antibiotics, Diuretics, and Gastrointestinal products. While specific market share comparisons and head-to-head analyses are not publicly available, the company's focus on high-demand therapeutic areas positions it to effectively compete in these segments.

2Key Differentiators

Avet Lifesciences Private Limited's key differentiators include its concentrated portfolio of high-demand pharmaceutical formulations, particularly in Advanced Antibiotics, Diuretics, and Gastrointestinal products. The company's commitment to obtaining WHO prequalification for its products enhances its credibility and facilitates access to emerging markets. Additionally, Avet Lifesciences' strategic focus on maintaining a diversified export strategy across multiple international markets mitigates concentration risk and supports sustainable growth.

3Strategic Position

Avet Lifesciences Private Limited's current strategic direction emphasizes the export of generic pharmaceutical formulations, with a strong focus on high-demand therapeutic categories. The company's pursuit of WHO prequalification and compliance with international GMP standards reflect its commitment to quality and global market access. Looking ahead, Avet Lifesciences is well-positioned to expand its presence in emerging markets and strengthen its competitive position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Avet Lifesciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Avet Lifesciences Private Limited has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $6.5 million USD across 135 shipments between 2022 and 2026. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its export value, indicating a focused and reliable supply chain. While specific reliability indicators are not publicly disclosed, the company's adherence to international GMP standards and pursuit of WHO prequalification suggest a commitment to quality and consistency in its manufacturing processes.

2Certifications to Verify

Importers should verify the following certifications when considering Avet Lifesciences Private Limited as a supplier:

WHO Prequalification: Confirms that the company's products meet international quality standards, facilitating access to emerging markets.

EU GMP Certification: Indicates compliance with European Union Good Manufacturing Practice standards, ensuring product quality and safety.

Frequently Asked Questions — Avet Lifesciences Private Limited

How many pharmaceutical products does Avet Lifesciences Private Limited export from India?

Avet Lifesciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Furosemide ($2.7M), Amikacin ($2.4M), Metoclopramide ($1.5M). Total export value is $6.5M.

What is Avet Lifesciences Private Limited's total pharmaceutical export value?

Avet Lifesciences Private Limited's total pharmaceutical export value is $6.5M, based on 135 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Avet Lifesciences Private Limited the #1 Indian exporter?

Avet Lifesciences Private Limited is the #1 Indian exporter in 1 products: Amikacin (11.1% market share).

What therapeutic categories does Avet Lifesciences Private Limited cover?

Avet Lifesciences Private Limited exports across 3 therapeutic categories. The largest are Diuretics (41.1%, 1 products), Advanced Antibiotics (36.0%, 1 products), Gastrointestinal (23.0%, 1 products).

Get Full Avet Lifesciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.